419 related articles for article (PubMed ID: 27601638)
1. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
3. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
Mohammadi Torbati P; Asadi F; Fard-Esfahani P
Asian Pac J Cancer Prev; 2019 May; 20(5):1453-1456. PubMed ID: 31127907
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples.
Liu HP; Lai HM; Guo Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32607548
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
9. Implications of microRNA dysregulation in the development of prostate cancer.
Massillo C; Dalton GN; Farré PL; De Luca P; De Siervi A
Reproduction; 2017 Oct; 154(4):R81-R97. PubMed ID: 28878093
[TBL] [Abstract][Full Text] [Related]
10. Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
Al-Qatati A; Akrong C; Stevic I; Pantel K; Awe J; Saranchuk J; Drachenberg D; Mai S; Schwarzenbach H
Int J Cancer; 2017 Sep; 141(6):1231-1239. PubMed ID: 28571116
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
12. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.
Guo X; Han T; Hu P; Guo X; Zhu C; Wang Y; Chang S
Int Urol Nephrol; 2018 Dec; 50(12):2193-2200. PubMed ID: 30324582
[TBL] [Abstract][Full Text] [Related]
13. High-Level Expression of microRNA-21 in Peripheral Blood Mononuclear Cells Is a Diagnostic and Prognostic Marker in Prostate Cancer.
Huang W; Kang XL; Cen S; Wang Y; Chen X
Genet Test Mol Biomarkers; 2015 Sep; 19(9):469-75. PubMed ID: 26247873
[TBL] [Abstract][Full Text] [Related]
14. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
16. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
17. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
McDonald AC; Vira M; Walter V; Shen J; Raman JD; Sanda MG; Patil D; Taioli E
Prostate; 2019 Jun; 79(9):961-968. PubMed ID: 30958910
[TBL] [Abstract][Full Text] [Related]
19. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.
Farran B; Dyson G; Craig D; Dombkowski A; Beebe-Dimmer JL; Powell IJ; Podgorski I; Heilbrun L; Bolton S; Bock CH
Carcinogenesis; 2018 Apr; 39(4):556-561. PubMed ID: 29471417
[TBL] [Abstract][Full Text] [Related]
20. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
